Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Gross Margin (2020 - 2025)

Cytek Biosciences' Gross Margin history spans 6 years, with the latest figure at 52.92% for Q4 2025.

  • For Q4 2025, Gross Margin fell 563.0% year-over-year to 52.92%; the TTM value through Dec 2025 reached 51.84%, down 358.0%, while the annual FY2025 figure was 51.84%, 358.0% down from the prior year.
  • Gross Margin reached 52.92% in Q4 2025 per CTKB's latest filing, roughly flat from 52.69% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 66.36% in Q3 2022 to a low of 27.21% in Q4 2021.
  • Average Gross Margin over 5 years is 52.96%, with a median of 56.7% recorded in 2023.
  • Peak YoY movement for Gross Margin: skyrocketed 8798bps in 2022, then tumbled -974bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 27.21% in 2021, then surged by 323bps to 60.77% in 2022, then fell by -7bps to 56.75% in 2023, then rose by 3bps to 58.55% in 2024, then decreased by -10bps to 52.92% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Gross Margin are 52.92% (Q4 2025), 52.69% (Q3 2025), and 52.34% (Q2 2025).